ibrutinib,venetoclax,Obinutuzumab
roche,janssen,abbvie,biogen
['ibru', 'triplet', 'cll']
cll 13 at eha22. vo remains the time limited soc. triplet giv not ready as soc in any setting. ibrutinib adds infections but not pfs! modern 1l time limited trials need to include vo to be relevant. vo will be directly compared to giv in future. 
Director, CLL program, MSKCC